Group 1: Overall Industry Outlook - In 2026, the pharmaceutical industry is expected to experience a surge in innovative drugs, a recovery in the CXO sector, transformation in traditional Chinese medicine, contraction of retail pharmacies, restructuring of hospitals, and a wave of mergers and acquisitions, leading to increased industry differentiation and stronger players remaining dominant [1] Group 2: Innovative Drugs - A total of 76 innovative drugs were approved in 2025, marking a 58% increase from the previous year, with over 150 licensing transactions totaling more than $130 billion, indicating robust growth in China's innovative drug sector [3] - Approximately 20 major innovative drugs are anticipated to be approved in China in 2026, covering various therapeutic areas including oncology and rare diseases, with notable examples such as BL-B01D1 for esophageal squamous carcinoma [3][4] Group 3: CXO Sector - The CXO (Contract Research Organization) industry is experiencing a recovery driven by external factors such as U.S. interest rate cuts and increased R&D investments from multinational pharmaceutical companies, alongside domestic demand for CRO services [5][6] - The penetration rate of outsourcing in areas like ADCs and oligonucleotides is expected to rise to 65%, with companies like WuXi AppTec and Kelun Biotech showing strong growth in these segments [6] Group 4: Traditional Chinese Medicine - The Chinese medicine sector is entering an era of refined management, driven by policy upgrades and market innovations, with a focus on quality and cost balance in procurement [7][9] - By the end of 2026, China aims to establish 180 domestic and 30 international standards for traditional Chinese medicine, with the market expected to exceed 1 trillion yuan for the first time in 2024 [9] Group 5: Medical Devices - The medical device industry is shifting from price suppression to innovation-driven growth, with domestic companies rapidly advancing in high-end imaging, surgical robots, and AI medical devices [10] - Chinese medical device companies are increasingly expanding into international markets, with a notable rise in export volumes expected by 2026 [10] Group 6: Retail Pharmacies - The offline pharmacy sector is projected to contract significantly due to the growth of O2O and B2C models, with over 15,975 stores closing by September 2025, reflecting a 73% year-on-year increase in closures [12][13] Group 7: Private Hospitals - Private hospitals are facing severe challenges, with an average of 1.4 closures per day in 2024, and this trend is expected to continue into 2026 due to regulatory pressures and financial difficulties [14][15]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [1] Core Views - The investment logic in the pharmaceutical sector is shifting from policy pressure to innovation-driven growth, with the "14th Five-Year Plan" directly supporting the development of innovative drugs and medical devices [8][26] - The industry is witnessing a transition from rapid following to original innovation, as demonstrated by Chinese companies showcasing their global competitiveness and pipeline value at the 2025 ESMO conference [8][26] - The recent approval of innovative drugs and the successful listing of companies on the STAR Market indicate a supportive capital market for innovative pharmaceutical enterprises [8][26] Industry Review - The pharmaceutical and biotechnology industry index increased by 1.89%, ranking 20th among 31 primary industries, underperforming the CSI 300 index which rose by 2.80% [5][16] - The sub-industries of medical research outsourcing and vaccines showed the highest gains, with increases of 5.26% and 4.19% respectively, while medical devices and traditional Chinese medicine experienced declines of 1.21% and 0.56% [5][16] - As of October 31, 2025, the industry’s PE (TTM, excluding negative values) was 30.67x, up from 30.08x in the previous period, indicating an upward valuation trend but still below the average [21] Company Dynamics - A total of 36 listed companies in the pharmaceutical and biotechnology sector experienced a net reduction in shareholder holdings amounting to 805 million yuan, with 4 companies increasing holdings by 120 million yuan and 32 companies reducing holdings by 925 million yuan [5][6] - Among the 501 tracked companies, 499 have disclosed their performance for the first three quarters of 2025, with 53 companies reporting a net profit growth of 100% or more, and 69 companies reporting growth between 30% and 100% [6] Investment Recommendations - Focus on companies with strong positions in innovative drugs and cutting-edge technology platforms, particularly those involved in ADC, bispecific/multispecific antibodies, and cell therapy, which can provide high potential for international market expansion [8] - Pay attention to the CXO industry, which is expected to see increased demand due to the recovery of innovative drug development and commercialization, especially for leading companies with strong service capabilities in new technology areas [8]

Core Viewpoint - The article highlights the significant advancements in the treatment of relapsed/refractory multiple myeloma through BCMA-targeted ADC therapies, particularly the promising results from the global DREAMM-7 study, which showcases the efficacy of the drug Mabeparatuzumab in improving patient outcomes [1][4][6]. Group 1: ADC Market and Innovations - The ADC sector has become a leading area for innovation in China, with over 22 related transactions last year totaling more than $20 billion [1]. - ADCs have demonstrated efficacy across various tumor types, including breast, gastric, and lung cancers, and are now making strides in treating multiple myeloma [1][2]. - The emergence of BCMA-targeted ADCs represents a new hope for patients with relapsed/refractory multiple myeloma, as highlighted by recent clinical findings [2][3]. Group 2: Clinical Study Results - The DREAMM-7 study included 494 patients and compared the efficacy of Mabeparatuzumab with the classic CD38 monoclonal antibody Daratumumab, revealing significant survival advantages for the Mabeparatuzumab group [4][5]. - In the Chinese subgroup of the DREAMM-7 study, the median progression-free survival (mPFS) for the Mabeparatuzumab group was not reached, while the Daratumumab group had an mPFS of 8.4 months [5]. - The complete response rate for the Mabeparatuzumab group was 50%, significantly higher than the 22.5% in the Daratumumab group, indicating a strong therapeutic potential [5][6]. Group 3: Safety and Regulatory Recognition - The safety profile of the BCMA ADC therapy in the Chinese subgroup was consistent with global findings, showing manageable safety [6]. - The National Medical Products Administration of China has granted breakthrough therapy designation to Mabeparatuzumab, indicating its potential as a significant treatment option for multiple myeloma patients [6][7]. - The results from the Chinese study reflect a shift in clinical research from a follower to a leader role, showcasing China's capabilities in developing breakthrough therapies [7].